Rich Pharmaceuticals (RCHA) 0.0016 $RCHA
Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug (IND) Application For The Treatment of Acute Myelocytic Leukemia
PR Newswire - Wed Feb 04, 8:45AM CST
Rich Pharmaceuticals, Inc. (OTCQB: RCHA) ("Rich" or the "Company"
, a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China. This new batch of RP-323 represents a new second-generation compound with improved product usability and stability. Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323. Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.
WSA Speaks to Three Companies on the Rise
Marketwired - Tue Dec 02, 10:27AM CST
ClearOne (NASDAQ: CLRO) CEO Zee Hakimoglu discussed the company's favorable Q3 results reporting 27% revenue growth from last year with solid profitability. She outlined ClearOne's products and patents and talked about two recent acquisitions and how these acquisitions have positioned ClearOne favorably in their traditional audio conferencing market as well as in the emerging media collaboration market.
CLRO: 10.19 (-0.12)
Rich Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application to FDA for the Treatment of Acute Myelocytic Leukemia and Myelodysplastic Syndrome
GlobeNewswire - Thu Oct 23, 6:09AM CDT
Rich Pharmaceuticals, Inc. (OTCQB:RCHA) ("Rich" or the "Company" , a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has submitted an investigational new drug (IND) application to conduct a Phase 2 clinical trial for its lead compound RP-323 in Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) with the U.S. Food and Drug Administration (FDA). Rich plans to initiate a multicenter, Phase 2 clinical study using RP-323 to treat AML and MDS patients. According to the American Cancer Society surveillance research group in 2014, it is estimated there will be 18,860 new cases of AML and 10,460 deaths from acute myeloid leukemia (AML) in the United States. Myelodysplastic syndrome is a type of cancer in which the bone marrow does not make enough healthy blood cells and there are abnormal (blast) cells in the blood and/or bone marrow.
Rich Pharmaceuticals Announces Assignment Agreement Acquiring Complete Ownership, Development and Commercialization Rights for Indication, Patents and Intellectual Property Related to the Treatment of Hodgkin's Lymphoma
GlobeNewswire - Mon Oct 13, 8:45AM CDT
Rich Pharmaceuticals, Inc. (OTCQB:RCHA) ("Rich" or the "Company" Rich, a cancer therapeutics development company announced that it has entered into an agreement with Richard L. Chang Holdings, LLC based in New Jersey for ownership to its investigational cancer patent assignment using Phorbol Esters in the treatment of Hodgkin's Lymphoma. Hodgkin lymphoma is a cancer of the immune system that is marked by the presence of a type of cell called the Reed-Sternberg cell. The two major types of Hodgkin Lymphoma are classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. Currently, this disease affects over 100,000 patients annually. In 2014, it is estimated that there will be 9,190 new cases of Hodgkin lymphoma and an estimated 1,180 people will die of this disease.
Rich Pharmaceuticals Announces Up to $4.5 Million Finance Deal to Fund Phase 2 Clinical Trials in Acute Myelocytic Leukemia
GlobeNewswire - Thu Oct 09, 6:00AM CDT
Rich Pharmaceuticals, Inc. (OTCQB:RCHA) ("Rich" or the "Company" Rich, a cancer therapeutics development company announced that it has entered into an investment agreement up to $4.5 Million with Macallan Partners, LLC headquartered in White Plains, NY. The investment commences under the Macallan Partners, LLC Agreement filed under Form S-1 and recently was declared effective by the Securities and Exchange Commission.
Rich Pharmaceuticals Hires Contract Research Organization to File NDA and Identify Clinical Trial Site(s) for Lead Compound
GlobeNewswire - Wed Jul 23, 6:00AM CDT
Rich Pharmaceuticals, Inc. (OTCQB:RCHA) ("Rich" or the "Company" announced the company has hired San Diego, CA based contract research organization (CRO) Therinova Development, Inc., to file its new drug application (NDA), identify and supervise Phase II clinical trial sites for the use of RP-323 in Acute Myelocytic Leukemia patients.
Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug (IND) Application For The Treatment of Acute Myelocytic Leukemia
PR Newswire - Wed Feb 04, 8:45AM CST
Rich Pharmaceuticals, Inc. (OTCQB: RCHA) ("Rich" or the "Company"
, a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China. This new batch of RP-323 represents a new second-generation compound with improved product usability and stability. Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323. Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials. WSA Speaks to Three Companies on the Rise
Marketwired - Tue Dec 02, 10:27AM CST
ClearOne (NASDAQ: CLRO) CEO Zee Hakimoglu discussed the company's favorable Q3 results reporting 27% revenue growth from last year with solid profitability. She outlined ClearOne's products and patents and talked about two recent acquisitions and how these acquisitions have positioned ClearOne favorably in their traditional audio conferencing market as well as in the emerging media collaboration market.
CLRO: 10.19 (-0.12)
Rich Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application to FDA for the Treatment of Acute Myelocytic Leukemia and Myelodysplastic Syndrome
GlobeNewswire - Thu Oct 23, 6:09AM CDT
Rich Pharmaceuticals, Inc. (OTCQB:RCHA) ("Rich" or the "Company"
, a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has submitted an investigational new drug (IND) application to conduct a Phase 2 clinical trial for its lead compound RP-323 in Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) with the U.S. Food and Drug Administration (FDA). Rich plans to initiate a multicenter, Phase 2 clinical study using RP-323 to treat AML and MDS patients. According to the American Cancer Society surveillance research group in 2014, it is estimated there will be 18,860 new cases of AML and 10,460 deaths from acute myeloid leukemia (AML) in the United States. Myelodysplastic syndrome is a type of cancer in which the bone marrow does not make enough healthy blood cells and there are abnormal (blast) cells in the blood and/or bone marrow. Rich Pharmaceuticals Announces Assignment Agreement Acquiring Complete Ownership, Development and Commercialization Rights for Indication, Patents and Intellectual Property Related to the Treatment of Hodgkin's Lymphoma
GlobeNewswire - Mon Oct 13, 8:45AM CDT
Rich Pharmaceuticals, Inc. (OTCQB:RCHA) ("Rich" or the "Company"
Rich, a cancer therapeutics development company announced that it has entered into an agreement with Richard L. Chang Holdings, LLC based in New Jersey for ownership to its investigational cancer patent assignment using Phorbol Esters in the treatment of Hodgkin's Lymphoma. Hodgkin lymphoma is a cancer of the immune system that is marked by the presence of a type of cell called the Reed-Sternberg cell. The two major types of Hodgkin Lymphoma are classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. Currently, this disease affects over 100,000 patients annually. In 2014, it is estimated that there will be 9,190 new cases of Hodgkin lymphoma and an estimated 1,180 people will die of this disease. Rich Pharmaceuticals Announces Up to $4.5 Million Finance Deal to Fund Phase 2 Clinical Trials in Acute Myelocytic Leukemia
GlobeNewswire - Thu Oct 09, 6:00AM CDT
Rich Pharmaceuticals, Inc. (OTCQB:RCHA) ("Rich" or the "Company"
Rich, a cancer therapeutics development company announced that it has entered into an investment agreement up to $4.5 Million with Macallan Partners, LLC headquartered in White Plains, NY. The investment commences under the Macallan Partners, LLC Agreement filed under Form S-1 and recently was declared effective by the Securities and Exchange Commission. Rich Pharmaceuticals Hires Contract Research Organization to File NDA and Identify Clinical Trial Site(s) for Lead Compound
GlobeNewswire - Wed Jul 23, 6:00AM CDT
Rich Pharmaceuticals, Inc. (OTCQB:RCHA) ("Rich" or the "Company"
announced the company has hired San Diego, CA based contract research organization (CRO) Therinova Development, Inc., to file its new drug application (NDA), identify and supervise Phase II clinical trial sites for the use of RP-323 in Acute Myelocytic Leukemia patients. 
